FIGURE

Figure 3

ID

ZDB-FIG-220422-11

Publication

Boddy et al., 2022 - Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosis

Other Figures

All Figure Page

Back to All Figure Page

Figure 3

Metabolites identified in an unbiased screen are significant in multiple robust MR measures. (A–C) Scatter plots demonstrating the correlation between genetic liability to serum estrone-3-sulphate (IVW P = 6.58e−05, beta = −0.03, se = 0.008) (A), bradykinin (IVW P = 8.07e-05, beta = −0.05, se = 0.01) (B), and isoleucine (IVW P = 1.29e−04, beta = 0.05, se = 0.01) (C), with genetic liability to ALS. Points indicate effect size (β) and standard errors for each SNP-outcome relationship. (D) Robust MR measures and sensitivity analyses for each MR analysis.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Brain Commun